Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
TRENDS
Drug Makers’ Payments to Medical Institutions Dip for Second Year: Jiho Tally
Pharmaceutical companies in Japan saw their payments to medical institutions dwindle 6% in FY2014, falling for the second straight year, with payouts for academic research support including controversial “scholarship donations” shrinking over 20%, according to a Jiho tally. The tally…
To read the full story
Related Article
- 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
October 1, 2018
- 74 Drug Makers Paid 483.1 Billion Yen to Healthcare Providers in FY2013: Jiho Tally
March 9, 2015
- Chugai Led in Research Grants Payment in FY2013; Grants Fell Among Major Drug Makers
November 5, 2014
TRENDS
- Top 10 PHARMA JAPAN Articles of 2025
December 23, 2025
- Top 10 PHARMA JAPAN Articles of 2024
December 25, 2024
- Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
- Top 10 PHARMA JAPAN Articles in 2022
December 28, 2022
- 15 APIs with 10 Billion Yen-Plus Peak Sales Outlooks Listed in 2021: Jiho Tally
December 28, 2021
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…